The Predictive Role of FGF21 in Acute Liver Injury Caused by Bacterial Infectious Diseases in Critical Care: A Retrospective Cohort Study

FGF21在重症监护中细菌感染引起的急性肝损伤中的预测作用:一项回顾性队列研究

阅读:1

Abstract

BACKGROUND: Acute liver injury (ALI) is a common complication in critically ill patients and has been strongly associated with adverse clinical outcomes. Early detection and timely management of ALI in these patients are crucial for implementing effective therapeutic strategies to prevent disease progression and improve patient outcomes. METHODS: In this study, 112 critically ill patients with bacterial infectious diseases were categorized into two groups based on the presence or absence of ALI within 24 hours of the intensive care unit (ICU) admission. Serum concentrations of fibroblast growth factor 21 (FGF21), interleukin(IL)-6, IL-22, IL-10, liver enzymes, hypersensitive C-reactive protein (hs-CRP), and D-Dimer (D2) were measured within 24 hours of ICU admission. Demographic and clinical data were recorded. Logistic regression analysis was performed to identify potentially predictive biomarkers for ALI. Receiver operating characteristic (ROC) curve analysis was employed to determine the optimal model for predicting ALI in critically ill patients. RESULTS: Patients in the ALI group exhibited significantly higher serum levels of IL-6, IL-10, IL-22, FGF21, liver enzymes, lactic acid, procalcitonin, D2, APACHE II scores, shorter survival time and higher 28-day mortality compared to those in the non-ALI group. Logistic regression analysis indicated that age, gender, plasma D2, and serum levels of direct bilirubin (DBIL), IL-22 and FGF21 were valuable predictors of ALI among critically ill patients. ROC curve revealed that this predictive model achieved a high area under the curve of 0.885, demonstrating excellent discriminatory ability. CONCLUSION: Elevated levels of serum FGF21 in the early stages of critical illness may represent a promising novel biomarker for predicting ALI.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。